TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21269443

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (matched according to mean age, sex, and general intelligence)
Number of subjects: 0
Study: 19227171

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg x day(‐1) + morphine 3.3 mg x day(‐1) (group MB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine 3.3 mg x day(‐1) alone (group M)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg x day(‐1) alone (group B)
Number of subjects: 100
Study: 16338599

Group type: EXPERIMENTAL
Intervention: Vitamin C (1g/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Magnesium (450 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 15085555

Group type: EXPERIMENTAL
Intervention: Glucose + fat-free yoghurt
Number of subjects: 4

Group type: COMPARATOR
Intervention: Glucose + full-fat yoghurt
Number of subjects: 4

Group type: COMPARATOR
Intervention: Aspartame + full-fat yoghurt
Number of subjects: 4

Group type: COMPARATOR
Intervention: Aspartame + fat-free yoghurt
Number of subjects: 4
Study: 11244702

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg.kg‐1) with non-invasive blood pressure measurement in the ipsilateral arm
Number of subjects: 31
Study: 9286852

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem SR 120 mg twice daily
Number of subjects: 0
Study: 8357095

Group type: EXPERIMENTAL
Intervention: Indobufen (B)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (C)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Indobufen and graduated compression stockings (D)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 224
Study: 3553586

Group type: EXPERIMENTAL
Intervention: Diclofenac (75, 100, or 125 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (75, 100, or 125 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study: 29504788

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce weight loss
Number of subjects: 4774

Group type: COMPARATOR
Intervention: Diabetes education and support control group
Number of subjects: 4774
Study: 27901219

Group type: EXPERIMENTAL
Intervention: Massage + Reiki (G2)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Massage + Rest (G1)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 122
Study: 24945556

Group type: EXPERIMENTAL
Intervention: Brief chair-side counselling by a dentist based on the 5 A's approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 70
Study: 22615841

Group type: EXPERIMENTAL
Intervention: Individually tailored guided self‐help treatment targeting depression and comorbid symptoms
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Standardized (non‐tailored) Internet‐based treatment for depression
Number of subjects: 121

Group type: COMPARATOR
Intervention: Active control group (monitored online discussion group)
Number of subjects: 121
Study: 20801727

Group type: EXPERIMENTAL
Intervention: Self-activation manipulation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 79
Study: 17715212

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiagabine (8 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiagabine (12 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiagabine (16 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17240931

Group type: EXPERIMENTAL
Intervention: Separated size 40 K3 rotary file with gutta-percha and AH-26 sealer
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Obturated without a separated file (Group 2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Negative control (obturated and sealed with nail varnish)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Positive control (obturated without sealer)
Number of subjects: 26
Study: 12472786

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate in sucrose (SFGC)
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2338
Study: 11052633

Group type: EXPERIMENTAL
Intervention: AVSS through commercially available virtual glasses (VG-AVSS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No AVSS
Number of subjects: 37
Study: 8851614

Group type: EXPERIMENTAL
Intervention: Oral fleroxacin; single-dose trial; specific dosage not mentioned.
Number of subjects: 0
Study: 1519232

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (5.000 anti XaU once daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard heparin (5.000 IU three times daily)
Number of subjects: 39
Study: 6666231

Group type: EXPERIMENTAL
Intervention: ISDN treatment (240 mg daily, 6 X 40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ISDN treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31860830

Group type: EXPERIMENTAL
Intervention: Forefoot Strike (FFS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rear-foot Strike (RFS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both FFS and RFS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LDH
Number of subjects: 18
Study: 28632486

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 63

Group type: COMPARATOR
Intervention: Switching taxane
Number of subjects: 63

Group type: COMPARATOR
Intervention: Not switching taxane
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Taxane-induced decrease in %ARNL
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 63
Study: 26555148

Group type: EXPERIMENTAL
Intervention: NMES treatment group (8-week daily NMES treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (usual or conventional treatments)
Number of subjects: 32
Study: 24789375

Group type: EXPERIMENTAL
Intervention: Patching (minimum of 6 h/d)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Atropine sulfate eyedrops, 1% (1 drop daily)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Both treatments (Patching and Atropine)
Number of subjects: 419
Study: 22078979

Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide (150 mg/12.5 mg day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nebivolol/hydrochlorothiazide (5 mg/12.5 mg day)
Number of subjects: 65
Study: 19284181

Group type: EXPERIMENTAL
Intervention: Colloidal-Q10 (new formulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solubilizate 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oil-based formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solubilizate 2
Number of subjects: 20
Study: 17888059

Group type: EXPERIMENTAL
Intervention: Moderate pressure massage therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 80
Study: 15135263

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 40
Study: 11922742

Group type: EXPERIMENTAL
Intervention: D2 dissection with gastrectomy
Number of subjects: 1403

Group type: COMPARATOR
Intervention: D1 dissection with gastrectomy
Number of subjects: 1403

Group type: COMPARATOR
Intervention: N1 group
Number of subjects: 1403

Group type: COMPARATOR
Intervention: N2 group
Number of subjects: 1403

Group type: COMPARATOR
Intervention: N3 group
Number of subjects: 1403
Study: 10808843

Group type: EXPERIMENTAL
Intervention: Armchair with integral pressure-reducing cushion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing bedside armchair (Control)
Number of subjects: 0
Study: 7602620

Group type: EXPERIMENTAL
Intervention: Surgical care supplemented with a psychosocial intervention program
Number of subjects: 820

Group type: COMPARATOR
Intervention: Surgical care
Number of subjects: 820
Study: 2294263

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (5 micrograms)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Papaverine (18 mg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Subjective preference
Number of subjects: 129
Study: 13094

Group type: EXPERIMENTAL
Intervention: 10 mg iv chlorpheniramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.5 mg/kg iv aminophylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8 mg po chlorpheniramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 30 mg po butabarbital
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 10
Study: 29064626

Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: hsCRP 1 to 3 mg/L
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: hsCRP >3 mg/L
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Low LDL-C and low hsCRP
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: Low LDL-C and high hsCRP
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: High LDL-C and low hsCRP
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: High LDL-C and high hsCRP
Number of subjects: 5380
Study: 27591455

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (Ropivacaine 0.15% plus Sufentanil 0.2μg/mL solution at 5mL/h)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Ropivacaine 0.1% plus Sufentanil 0.2μg/mL at 10mL/h)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Same solution as group A)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (Group A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (Group B and C)
Number of subjects: 130
Study: 24852915

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TWA ≥47 μV
Number of subjects: 210
Study: 22408272

Group type: EXPERIMENTAL
Intervention: Spinal mixture of bupivacaine and morphine followed by oral oxycodone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 50
Study: 19597422

Group type: EXPERIMENTAL
Intervention: Plerixafor (0.24 mg/kg) and G-CSF (10 microg/kg for 4 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Plerixafor and G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 35
Study: 18456059

Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee arthroplasty
Number of subjects: 104

Group type: COMPARATOR
Intervention: Mobile-bearing total knee arthroplasty
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 16162699

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone propionate, 1,000 microg/d) for 4 weeks
Number of subjects: 86
Study: 11409425

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (t-PA) in patients with Apo E2 phenotype (27 patients)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (t-PA) in patients without Apo E2 phenotype (190 patients)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo in patients with Apo E2 phenotype (31 patients)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Apo E4 phenotype (111 patients, 27% of total)
Number of subjects: 409
Study: 9609523

Group type: EXPERIMENTAL
Intervention: Oral pamidronate 300 mg daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 7920126

Group type: EXPERIMENTAL
Intervention: Mineral salt (sodium: potassium: magnesium 8:6:1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Common salt
Number of subjects: 100
Study: 3406540

Group type: EXPERIMENTAL
Intervention: Intravitreal infusion of thrombin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diathermy
Number of subjects: 0
Study: 2021881

Group type: EXPERIMENTAL
Intervention: Regular aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: As required aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Number of subjects: 60
Study: 329786

Group type: EXPERIMENTAL
Intervention: perphenazine, 20 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: amitriptyline, 125 mg/day with perphenazine, 20 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 31601530

Group type: EXPERIMENTAL
Intervention: Housing First with assertive community treatment (HF-ACT)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Housing First with intensive case management (HF-ICM) or ethnoracial-specific ICM services (HF-ER-ICM)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 575
Study: 27699657

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 15 mg/day, sulfasalazine 1 g/day, and HCQ 400 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hydroxychloroquine monotherapy (HCQ 400 mg/day)
Number of subjects: 72
Study: 26366885

Group type: EXPERIMENTAL
Intervention: Message including the cost of a missed appointment to the health system
Number of subjects: 19959

Group type: COMPARATOR
Intervention: Existing reminder message
Number of subjects: 19959

Group type: EXPERIMENTAL
Intervention: General terms message expressing the cost concept
Number of subjects: 19959

Group type: EXPERIMENTAL
Intervention: Moving from the existing reminder to the more effective costs message
Number of subjects: 19959
Study: 23406821

Group type: EXPERIMENTAL
Intervention: Emotion regulation training followed by CBT (Skills/CBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supportive counselling followed by CBT (Support/CBT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Skills/CBT
Number of subjects: 70
Study: 21844504

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fluoropyrimidine-cisplatin
Number of subjects: 774

Group type: COMPARATOR
Intervention: Placebo plus fluoropyrimidine-cisplatin
Number of subjects: 774
Study: 19624547

Group type: EXPERIMENTAL
Intervention: BoNT/A (5 U)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (isotonic saline)
Number of subjects: 14
Study: 17675277

Group type: EXPERIMENTAL
Intervention: 1000 mg alpha-linolenic acid per day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 9
Study: 15193889

Group type: EXPERIMENTAL
Intervention: Computer-tailored information
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: General information
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Computer-tailored information and General information
Number of subjects: 1500
Study: 11642634

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 6 months (Group 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 12 months (Group 2)
Number of subjects: 57
Study: 9699707

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus slow-release melatonin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 19
Study: 7986651

Group type: EXPERIMENTAL
Intervention: Specialized program (N = 82)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Traditional program (N = 131)
Number of subjects: 213
Study: 2646266

Group type: EXPERIMENTAL
Intervention: Megestrol 40 mg PO tid
Number of subjects: 197

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 1 mg PO tid
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both Megestrol and DES
Number of subjects: 197
Study: 31220256

Group type: EXPERIMENTAL
Intervention: Oral antimicrobial regimen (colistin 2×10^6 IU 4×/day, gentamicin 80 mg 4×/day, fosfomycin 3 g every 72 h)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral antimicrobial regimen
Number of subjects: 47
Study: 28403619

Group type: EXPERIMENTAL
Intervention: FTC/TDF+EFV
Number of subjects: 415

Group type: COMPARATOR
Intervention: 3TC/ZDV+EFV
Number of subjects: 415
Study: 26338525

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab in RAS and BRAF wild-type subgroup
Number of subjects: 508

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in RAS-mutation-positive subgroup
Number of subjects: 508

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in BRAF-mutation-positive subgroup
Number of subjects: 508
Study: 23421731

Group type: EXPERIMENTAL
Intervention: Amitriptyline 0.5 mg/kg/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topiramate 25 mg/d increasing up to 100 mg/d
Number of subjects: 57
Study: 21459374

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo transfer (ET)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Transabdominal ultrasound-guided embryo transfer (ET)
Number of subjects: 330
Study: 19825037

Group type: EXPERIMENTAL
Intervention: DentaPort ZX
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 831

Group type: COMPARATOR
Intervention: Comparison between DentaPort ZX and Raypex 5
Number of subjects: 831

Group type: COMPARATOR
Intervention: Comparison among same tooth type
Number of subjects: 831

Group type: COMPARATOR
Intervention: Comparison among different tooth types in the same group
Number of subjects: 831
Study: 16716324

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 3-6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin treatment for >6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin treatment overall
Number of subjects: 0
Study: 15477546

Group type: EXPERIMENTAL
Intervention: Oral cannabis extract
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11740797

Group type: EXPERIMENTAL
Intervention: Treatment with anti-CD4 monoclonal antibodies or anticytokine agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cell vaccination and T-cell receptor peptide vaccination targeting autoreactive T cells
Number of subjects: 0
Study: 9455619

Group type: EXPERIMENTAL
Intervention: Myocardial-free carnitine levels in patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Myocardial-free carnitine levels in control group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Plasma-free carnitine levels in patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Plasma-free carnitine levels in control group
Number of subjects: 11
Study: 7888291

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms day‐1 (B800)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms day‐1 (B1600)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluticasone 750 micrograms day‐1 (F750)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluticasone 1500 micrograms day‐1 (F1500)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Budesonide and Fluticasone (both doses)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms day‐1 (B1600) and Fluticasone 1500 micrograms day‐1 (F1500)
Number of subjects: 9
Study: 3283296

Group type: EXPERIMENTAL
Intervention: Propranolol-LA (long-acting formulation) at doses of 160, 240, and 320 mg once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional propranolol at 80 mg three times daily
Number of subjects: 15
Study: 31630566

Group type: EXPERIMENTAL
Intervention: Aging Mastery Program (AMP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 30298552

Group type: EXPERIMENTAL
Intervention: Fluid loading (1 g sodium chloride/125 mL of water starting 2.5-h before LBNP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluid loading
Number of subjects: 9

Group type: COMPARATOR
Intervention: No fluid loading (control)
Number of subjects: 9
Study: 26745622

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy (MBT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 24022566

Group type: EXPERIMENTAL
Intervention: L-arginine (20g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22872030

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (3 × 6.5 × 10⁹ CFU) for 3 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 28
Study: 20404219

Group type: EXPERIMENTAL
Intervention: Amlodipine-valsartan combination (5/80 mg and then 10/160 mg)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Amlodipine-atenolol combination (5/50 mg and then 10/100 mg)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Amlodipine-valsartan combination
Number of subjects: 393

Group type: COMPARATOR
Intervention: Amlodipine-atenolol combination
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 393
Study: 19051744

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 0
Study: 15802904

Group type: EXPERIMENTAL
Intervention: omega3 fatty acid‐enhanced supplement
Number of subjects: 73

Group type: COMPARATOR
Intervention: arginine‐enhanced supplement
Number of subjects: 73
Study: 12439084

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10048064

Group type: EXPERIMENTAL
Intervention: Holmium Yag laser radiation
Number of subjects: 18